Expression of matrix metalloproteinases in feline vaccine site-associated sarcomas.
OBJECTIVE
To screen for expression of 9 predominant members of the matrix metalloproteinase (MMP) family, including membrane-type matrix metalloproteinases (MT-MMPs) and tissue inhibitors of metalloproteinases (TIMPs), in primary tumor tissue biopsy specimens of vaccine site-associated sarcomas (VSS) in cats and compare expression profiles of VSS with expression profiles of non-VSS and carcinomas.


METHODS
31 primary tumor tissue biopsy specimens and 6 nontumor (normal) tissue biopsy specimens.


METHODS
Tissue specimens were obtained from primary tumor biopsy specimens of cats. Primers for reverse transcriptase-polymerase chain reaction assay were designed on the basis of known sequences. Data were analyzed for patterns of expression of MMPs, MT-MMPs, and TIMPs. Differences in expression patterns were evaluated among cats of differing genders, ages, metastasis status, and overall survival durations, and between cats with VSS and cats with non-VSS tumor types.


RESULTS
A total of 31 primary tumor tissue biopsy specimens and 6 nontumor (normal) tissue biopsy specimens were screened for the presence of 6 MMPs and 3 TIMPs. Matrix metalloproteinase and TIMP expression was found in non-VSS, carcinomas, and VSS. No significant differences were found in patterns of expression among tumor types. Metastasis was found to be the only predictive factor for overall survival duration. A significant correlation was found between MMP2 and MT-MMP16 expression and overall duration of survival.


CONCLUSIONS
The identification of MMPs in feline VSS supports an underlying inflammatory pathogenesis for this tumor. Expression of MMP2 and MT-MMP16 were correlated with survival time in our study.
Sorensen
Kara C
KC
Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL 61802, USA.
Kitchell
Barbara E
BE
Schaeffer
David J
DJ
Mardis
Paul E
PE
D000704:Analysis of Variance; D000818:Animals; D001483:Base Sequence; D001706:Biopsy; D002371:Cat Diseases / Q000378:metabolism* / Q000401:mortality; D002415:Cats; D017931:DNA Primers; D018076:DNA, Complementary / Q000235:genetics; D004587:Electrophoresis, Agar Gel; D020782:Matrix Metalloproteinases / Q000235:genetics / Q000378:metabolism*; D008969:Molecular Sequence Data; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012509:Sarcoma / Q000378:metabolism / Q000473:pathology / Q000662:veterinary*; D017422:Sequence Analysis, DNA; D012878:Skin Neoplasms / Q000378:metabolism / Q000473:pathology / Q000662:veterinary*; D019714:Tissue Inhibitor of Metalloproteinases / Q000235:genetics / Q000378:metabolism*; D014611:Vaccination / Q000009:adverse effects / Q000662:veterinary*
D017931:DNA Primers; D018076:DNA, Complementary; D019714:Tissue Inhibitor of Metalloproteinases; D020782:Matrix Metalloproteinases